Loading...
Market
Novo Nordisk U.S. market share for weight-loss treatments by Dec 31, 2024?
5
Resolution / Starting Odds
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 34%
Market research reports from firms like IMS Health, Nielsen, or other market analytics firms
Story
Novo Nordisk to Invest $4.1 Billion in North Carolina Facility, Creating 1,000 Jobs to Boost Wegovy, Ozempic Production
Jun 24, 2024, 06:29 PM
Novo Nordisk has announced a $4.1 billion investment to build a new manufacturing facility in North Carolina. The facility will focus on increasing the production of its popular weight-loss treatment Wegovy and diabetes drug Ozempic. This expansion is part of a broader strategy to bolster its U.S. manufacturing capabilities, with a total investment of $6.8 billion by 2024. The new plant in Clayton, North Carolina, is expected to create over 1,000 new jobs. The move comes amid rising discontent in the U.S. over the high cost of these drugs, with figures like Senator Bernie Sanders criticizing the price disparity between the U.S. and other countries.
View original story
Similar markets
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Increase • 25%
Decrease • 25%
Remain the same • 25%
Other • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Leader in the sector • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Outside top 5 • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Increase by over 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%